Adverse	B:C0877248
events	I:C0877248
risk	O
associated	O
with	O
angiogenesis	O
inhibitors	I:C0596087
addition	O
to	O
therapy	O
in	O
ovarian	O
cancer	I:C0029925
:	O
a	O
meta-analysis	O
of	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
.	O

Adverse	O
events	I:C0877248
risk	O
associated	O
with	O
angiogenesis	B:C0596087
inhibitors	I:C0596087
addition	O
to	O
therapy	O
in	O
ovarian	O
cancer	I:C0029925
:	O
a	O
meta-analysis	O
of	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
.	O

Adverse	O
events	I:C0877248
risk	O
associated	O
with	O
angiogenesis	O
inhibitors	I:C0596087
addition	O
to	O
therapy	B:C0087111
in	O
ovarian	O
cancer	I:C0029925
:	O
a	O
meta-analysis	O
of	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
.	O

Adverse	O
events	I:C0877248
risk	O
associated	O
with	O
angiogenesis	O
inhibitors	I:C0596087
addition	O
to	O
therapy	O
in	O
ovarian	B:C0029925
cancer	I:C0029925
:	O
a	O
meta-analysis	O
of	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
.	O

Adverse	O
events	I:C0877248
risk	O
associated	O
with	O
angiogenesis	O
inhibitors	I:C0596087
addition	O
to	O
therapy	O
in	O
ovarian	O
cancer	I:C0029925
:	O
a	O
meta-analysis	B:C0920317
of	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
.	O

Adverse	O
events	I:C0877248
risk	O
associated	O
with	O
angiogenesis	O
inhibitors	I:C0596087
addition	O
to	O
therapy	O
in	O
ovarian	O
cancer	I:C0029925
:	O
a	O
meta-analysis	O
of	O
randomized	B:C0206035
controlled	I:C0206035
trials	I:C0206035
.	O

Inhibition	B:C1510884
of	I:C1510884
angiogenesis	I:C1510884
has	O
been	O
regarded	O
as	O
an	O
attractive	O
treatment	O
strategy	I:C0087111
for	O
advanced	O
or	O
recurrent	O
ovarian	I:C0278689
cancer	I:C0278689
.	O

Inhibition	O
of	I:C1510884
angiogenesis	I:C1510884
has	O
been	O
regarded	O
as	O
an	O
attractive	O
treatment	B:C0087111
strategy	I:C0087111
for	O
advanced	O
or	O
recurrent	O
ovarian	I:C0278689
cancer	I:C0278689
.	O

Inhibition	O
of	I:C1510884
angiogenesis	I:C1510884
has	O
been	O
regarded	O
as	O
an	O
attractive	O
treatment	O
strategy	I:C0087111
for	O
advanced	B:C0029925
or	O
recurrent	O
ovarian	I:C0278689
cancer	I:C0278689
.	O

Inhibition	O
of	I:C1510884
angiogenesis	I:C1510884
has	O
been	O
regarded	O
as	O
an	O
attractive	O
treatment	O
strategy	I:C0087111
for	O
advanced	O
or	O
recurrent	B:C0278689
ovarian	I:C0278689
cancer	I:C0278689
.	O

We	O
conduct	O
this	O
meta-analysis	B:C0920317
to	O
investigate	O
the	O
risk	O
of	O
adverse	O
events	I:C0877248
of	O
special	O
interest	O
related	O
to	O
angiogenesis	O
inhibitors	I:C0596087
(	O
angiogenesis	O
inhibitors	I:C0596087
)	O
in	O
ovarian	O
cancer	I:C0029925
.	O

We	O
conduct	O
this	O
meta-analysis	O
to	O
investigate	O
the	O
risk	O
of	O
adverse	B:C0877248
events	I:C0877248
of	O
special	O
interest	O
related	O
to	O
angiogenesis	O
inhibitors	I:C0596087
(	O
angiogenesis	O
inhibitors	I:C0596087
)	O
in	O
ovarian	O
cancer	I:C0029925
.	O

We	O
conduct	O
this	O
meta-analysis	O
to	O
investigate	O
the	O
risk	O
of	O
adverse	O
events	I:C0877248
of	O
special	O
interest	O
related	O
to	O
angiogenesis	B:C0596087
inhibitors	I:C0596087
(	O
angiogenesis	O
inhibitors	I:C0596087
)	O
in	O
ovarian	O
cancer	I:C0029925
.	O

We	O
conduct	O
this	O
meta-analysis	O
to	O
investigate	O
the	O
risk	O
of	O
adverse	O
events	I:C0877248
of	O
special	O
interest	O
related	O
to	O
angiogenesis	O
inhibitors	I:C0596087
(	O
angiogenesis	B:C0596087
inhibitors	I:C0596087
)	O
in	O
ovarian	O
cancer	I:C0029925
.	O

We	O
conduct	O
this	O
meta-analysis	O
to	O
investigate	O
the	O
risk	O
of	O
adverse	O
events	I:C0877248
of	O
special	O
interest	O
related	O
to	O
angiogenesis	O
inhibitors	I:C0596087
(	O
angiogenesis	O
inhibitors	I:C0596087
)	O
in	O
ovarian	B:C0029925
cancer	I:C0029925
.	O

Databases	B:C0242356
from	O
PubMed	O
,	O
Web	O
of	I:C0282574
Science	I:C0282574
and	O
Cochrane	O
library	I:C0023621
up	O
to	O
December	O
2015	O
were	O
searched	O
to	O
identify	O
relevant	O
studies	O
.	O

Databases	O
from	O
PubMed	B:C1138432
,	O
Web	O
of	I:C0282574
Science	I:C0282574
and	O
Cochrane	O
library	I:C0023621
up	O
to	O
December	O
2015	O
were	O
searched	O
to	O
identify	O
relevant	O
studies	O
.	O

Databases	O
from	O
PubMed	O
,	O
Web	B:C0282574
of	I:C0282574
Science	I:C0282574
and	O
Cochrane	O
library	I:C0023621
up	O
to	O
December	O
2015	O
were	O
searched	O
to	O
identify	O
relevant	O
studies	O
.	O

Databases	O
from	O
PubMed	O
,	O
Web	O
of	I:C0282574
Science	I:C0282574
and	O
Cochrane	B:C0023621
library	I:C0023621
up	O
to	O
December	O
2015	O
were	O
searched	O
to	O
identify	O
relevant	O
studies	O
.	O

Databases	O
from	O
PubMed	O
,	O
Web	O
of	I:C0282574
Science	I:C0282574
and	O
Cochrane	O
library	I:C0023621
up	O
to	O
December	O
2015	O
were	O
searched	O
to	O
identify	O
relevant	O
studies	B:C2603343
.	O

Eligible	O
studies	B:C2603343
included	O
prospective	O
randomized	I:C0206035
controlled	I:C0206035
phase	I:C0206035
II	I:C0206035
/	I:C0206035
III	I:C0206035
clinical	I:C0206035
trials	I:C0206035
evaluating	O
therapy	O
with	O
or	O
without	O
angiogenesis	O
inhibitors	I:C0596087
for	O
ovarian	O
cancer	I:C0029925
.	O

Eligible	O
studies	O
included	O
prospective	B:C0206035
randomized	I:C0206035
controlled	I:C0206035
phase	I:C0206035
II	I:C0206035
/	I:C0206035
III	I:C0206035
clinical	I:C0206035
trials	I:C0206035
evaluating	O
therapy	O
with	O
or	O
without	O
angiogenesis	O
inhibitors	I:C0596087
for	O
ovarian	O
cancer	I:C0029925
.	O

Eligible	O
studies	O
included	O
prospective	O
randomized	I:C0206035
controlled	I:C0206035
phase	I:C0206035
II	I:C0206035
/	I:C0206035
III	I:C0206035
clinical	I:C0206035
trials	I:C0206035
evaluating	B:C0557980
therapy	O
with	O
or	O
without	O
angiogenesis	O
inhibitors	I:C0596087
for	O
ovarian	O
cancer	I:C0029925
.	O

Eligible	O
studies	O
included	O
prospective	O
randomized	I:C0206035
controlled	I:C0206035
phase	I:C0206035
II	I:C0206035
/	I:C0206035
III	I:C0206035
clinical	I:C0206035
trials	I:C0206035
evaluating	O
therapy	B:C0087111
with	O
or	O
without	O
angiogenesis	O
inhibitors	I:C0596087
for	O
ovarian	O
cancer	I:C0029925
.	O

Eligible	O
studies	O
included	O
prospective	O
randomized	I:C0206035
controlled	I:C0206035
phase	I:C0206035
II	I:C0206035
/	I:C0206035
III	I:C0206035
clinical	I:C0206035
trials	I:C0206035
evaluating	O
therapy	O
with	O
or	O
without	O
angiogenesis	B:C0596087
inhibitors	I:C0596087
for	O
ovarian	O
cancer	I:C0029925
.	O

Eligible	O
studies	O
included	O
prospective	O
randomized	I:C0206035
controlled	I:C0206035
phase	I:C0206035
II	I:C0206035
/	I:C0206035
III	I:C0206035
clinical	I:C0206035
trials	I:C0206035
evaluating	O
therapy	O
with	O
or	O
without	O
angiogenesis	O
inhibitors	I:C0596087
for	O
ovarian	B:C0029925
cancer	I:C0029925
.	O

Summary	O
relative	O
risk	O
(	O
RR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
calculated	O
using	O
random	O
-	O
effects	O
or	O
fixed	O
-	O
effects	O
according	O
to	O
the	O
heterogeneity	O
among	O
included	O
trials	B:C0008976
.	O

A	O
total	O
of	O
7,761	O
patients	O
from	O
ten	O
clinical	B:C0008976
trials	I:C0008976
were	O
included	O
in	O
the	O
meta-	O
analysis	I:C0920317
.	O

A	O
total	O
of	O
7,761	O
patients	O
from	O
ten	O
clinical	O
trials	I:C0008976
were	O
included	O
in	O
the	O
meta-	B:C0920317
analysis	I:C0920317
.	O

Pooled	O
RR	O
showed	O
that	O
the	O
use	O
of	O
angiogenesis	B:C0596087
inhibitors	I:C0596087
was	O
associated	O
with	O
a	O
statistically	O
increased	O
risk	O
in	O
four	O
of	O
the	O
adverse	O
outcomes	O
studied	O
:	O
arterial	O
thromboembolic	I:C3544094
events	O
(	O
RR	O
=	O
2.0	O
)	O
,	O
gastrointestinal	O
(	I:C0151664
GI	I:C0151664
)	I:C0151664
perforation	I:C0151664
(	O
RR	O
=	O
3.86	O
)	O
,	O
proteinuria	O
(	O
RR	O
=	O
2.44	O
)	O
,	O
and	O
hypertension	O
(	O
RR	O
=	O
5.39	O
)	O
.	O

Pooled	O
RR	O
showed	O
that	O
the	O
use	O
of	O
angiogenesis	O
inhibitors	I:C0596087
was	O
associated	O
with	O
a	O
statistically	O
increased	O
risk	O
in	O
four	O
of	O
the	O
adverse	O
outcomes	O
studied	O
:	O
arterial	B:C3544094
thromboembolic	I:C3544094
events	O
(	O
RR	O
=	O
2.0	O
)	O
,	O
gastrointestinal	O
(	I:C0151664
GI	I:C0151664
)	I:C0151664
perforation	I:C0151664
(	O
RR	O
=	O
3.86	O
)	O
,	O
proteinuria	O
(	O
RR	O
=	O
2.44	O
)	O
,	O
and	O
hypertension	O
(	O
RR	O
=	O
5.39	O
)	O
.	O

Pooled	O
RR	O
showed	O
that	O
the	O
use	O
of	O
angiogenesis	O
inhibitors	I:C0596087
was	O
associated	O
with	O
a	O
statistically	O
increased	O
risk	O
in	O
four	O
of	O
the	O
adverse	O
outcomes	O
studied	O
:	O
arterial	O
thromboembolic	I:C3544094
events	O
(	O
RR	O
=	O
2.0	O
)	O
,	O
gastrointestinal	B:C0151664
(	I:C0151664
GI	I:C0151664
)	I:C0151664
perforation	I:C0151664
(	O
RR	O
=	O
3.86	O
)	O
,	O
proteinuria	O
(	O
RR	O
=	O
2.44	O
)	O
,	O
and	O
hypertension	O
(	O
RR	O
=	O
5.39	O
)	O
.	O

Pooled	O
RR	O
showed	O
that	O
the	O
use	O
of	O
angiogenesis	O
inhibitors	I:C0596087
was	O
associated	O
with	O
a	O
statistically	O
increased	O
risk	O
in	O
four	O
of	O
the	O
adverse	O
outcomes	O
studied	O
:	O
arterial	O
thromboembolic	I:C3544094
events	O
(	O
RR	O
=	O
2.0	O
)	O
,	O
gastrointestinal	O
(	I:C0151664
GI	I:C0151664
)	I:C0151664
perforation	I:C0151664
(	O
RR	O
=	O
3.86	O
)	O
,	O
proteinuria	B:C0033687
(	O
RR	O
=	O
2.44	O
)	O
,	O
and	O
hypertension	O
(	O
RR	O
=	O
5.39	O
)	O
.	O

Pooled	O
RR	O
showed	O
that	O
the	O
use	O
of	O
angiogenesis	O
inhibitors	I:C0596087
was	O
associated	O
with	O
a	O
statistically	O
increased	O
risk	O
in	O
four	O
of	O
the	O
adverse	O
outcomes	O
studied	O
:	O
arterial	O
thromboembolic	I:C3544094
events	O
(	O
RR	O
=	O
2.0	O
)	O
,	O
gastrointestinal	O
(	I:C0151664
GI	I:C0151664
)	I:C0151664
perforation	I:C0151664
(	O
RR	O
=	O
3.86	O
)	O
,	O
proteinuria	O
(	O
RR	O
=	O
2.44	O
)	O
,	O
and	O
hypertension	B:C0020538
(	O
RR	O
=	O
5.39	O
)	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
found	O
for	O
hemorrhagic	B:C0019080
events	O
(	O
p	O
=	O
0.07	O
)	O
,	O
venous	O
thromboembolic	I:C1861172
events	O
(	O
p	O
=	O
0.13	O
)	O
,	O
or	O
fatal	O
adverse	O
events	I:C0877248
(	O
p	O
=	O
0.26	O
)	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
found	O
for	O
hemorrhagic	O
events	O
(	O
p	O
=	O
0.07	O
)	O
,	O
venous	B:C1861172
thromboembolic	I:C1861172
events	O
(	O
p	O
=	O
0.13	O
)	O
,	O
or	O
fatal	O
adverse	O
events	I:C0877248
(	O
p	O
=	O
0.26	O
)	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
found	O
for	O
hemorrhagic	O
events	O
(	O
p	O
=	O
0.07	O
)	O
,	O
venous	O
thromboembolic	I:C1861172
events	O
(	O
p	O
=	O
0.13	O
)	O
,	O
or	O
fatal	O
adverse	B:C0877248
events	I:C0877248
(	O
p	O
=	O
0.26	O
)	O
.	O

The	O
addition	O
of	O
angiogenesis	B:C0596087
inhibitors	I:C0596087
to	O
therapy	O
in	O
ovarian	O
cancer	I:C0029925
did	O
significantly	O
increase	O
the	O
risk	O
of	O
arterial	O
thromboembolic	I:C3544094
events	O
,	O
GI	O
perforation	I:C0151664
,	O
proteinuria	O
and	O
hypertension	O
,	O
but	O
not	O
for	O
venous	O
thromboembolic	I:C1861172
events	O
,	O
hemorrhagic	O
events	O
,	O
or	O
fatal	O
adverse	O
events	I:C0877248
.	O

The	O
addition	O
of	O
angiogenesis	O
inhibitors	I:C0596087
to	O
therapy	B:C0087111
in	O
ovarian	O
cancer	I:C0029925
did	O
significantly	O
increase	O
the	O
risk	O
of	O
arterial	O
thromboembolic	I:C3544094
events	O
,	O
GI	O
perforation	I:C0151664
,	O
proteinuria	O
and	O
hypertension	O
,	O
but	O
not	O
for	O
venous	O
thromboembolic	I:C1861172
events	O
,	O
hemorrhagic	O
events	O
,	O
or	O
fatal	O
adverse	O
events	I:C0877248
.	O

The	O
addition	O
of	O
angiogenesis	O
inhibitors	I:C0596087
to	O
therapy	O
in	O
ovarian	B:C0029925
cancer	I:C0029925
did	O
significantly	O
increase	O
the	O
risk	O
of	O
arterial	O
thromboembolic	I:C3544094
events	O
,	O
GI	O
perforation	I:C0151664
,	O
proteinuria	O
and	O
hypertension	O
,	O
but	O
not	O
for	O
venous	O
thromboembolic	I:C1861172
events	O
,	O
hemorrhagic	O
events	O
,	O
or	O
fatal	O
adverse	O
events	I:C0877248
.	O

The	O
addition	O
of	O
angiogenesis	O
inhibitors	I:C0596087
to	O
therapy	O
in	O
ovarian	O
cancer	I:C0029925
did	O
significantly	O
increase	O
the	O
risk	O
of	O
arterial	B:C3544094
thromboembolic	I:C3544094
events	O
,	O
GI	O
perforation	I:C0151664
,	O
proteinuria	O
and	O
hypertension	O
,	O
but	O
not	O
for	O
venous	O
thromboembolic	I:C1861172
events	O
,	O
hemorrhagic	O
events	O
,	O
or	O
fatal	O
adverse	O
events	I:C0877248
.	O

The	O
addition	O
of	O
angiogenesis	O
inhibitors	I:C0596087
to	O
therapy	O
in	O
ovarian	O
cancer	I:C0029925
did	O
significantly	O
increase	O
the	O
risk	O
of	O
arterial	O
thromboembolic	I:C3544094
events	O
,	O
GI	B:C0151664
perforation	I:C0151664
,	O
proteinuria	O
and	O
hypertension	O
,	O
but	O
not	O
for	O
venous	O
thromboembolic	I:C1861172
events	O
,	O
hemorrhagic	O
events	O
,	O
or	O
fatal	O
adverse	O
events	I:C0877248
.	O

The	O
addition	O
of	O
angiogenesis	O
inhibitors	I:C0596087
to	O
therapy	O
in	O
ovarian	O
cancer	I:C0029925
did	O
significantly	O
increase	O
the	O
risk	O
of	O
arterial	O
thromboembolic	I:C3544094
events	O
,	O
GI	O
perforation	I:C0151664
,	O
proteinuria	B:C0033687
and	O
hypertension	O
,	O
but	O
not	O
for	O
venous	O
thromboembolic	I:C1861172
events	O
,	O
hemorrhagic	O
events	O
,	O
or	O
fatal	O
adverse	O
events	I:C0877248
.	O

The	O
addition	O
of	O
angiogenesis	O
inhibitors	I:C0596087
to	O
therapy	O
in	O
ovarian	O
cancer	I:C0029925
did	O
significantly	O
increase	O
the	O
risk	O
of	O
arterial	O
thromboembolic	I:C3544094
events	O
,	O
GI	O
perforation	I:C0151664
,	O
proteinuria	O
and	O
hypertension	B:C0020538
,	O
but	O
not	O
for	O
venous	O
thromboembolic	I:C1861172
events	O
,	O
hemorrhagic	O
events	O
,	O
or	O
fatal	O
adverse	O
events	I:C0877248
.	O

The	O
addition	O
of	O
angiogenesis	O
inhibitors	I:C0596087
to	O
therapy	O
in	O
ovarian	O
cancer	I:C0029925
did	O
significantly	O
increase	O
the	O
risk	O
of	O
arterial	O
thromboembolic	I:C3544094
events	O
,	O
GI	O
perforation	I:C0151664
,	O
proteinuria	O
and	O
hypertension	O
,	O
but	O
not	O
for	O
venous	B:C1861172
thromboembolic	I:C1861172
events	O
,	O
hemorrhagic	O
events	O
,	O
or	O
fatal	O
adverse	O
events	I:C0877248
.	O

The	O
addition	O
of	O
angiogenesis	O
inhibitors	I:C0596087
to	O
therapy	O
in	O
ovarian	O
cancer	I:C0029925
did	O
significantly	O
increase	O
the	O
risk	O
of	O
arterial	O
thromboembolic	I:C3544094
events	O
,	O
GI	O
perforation	I:C0151664
,	O
proteinuria	O
and	O
hypertension	O
,	O
but	O
not	O
for	O
venous	O
thromboembolic	I:C1861172
events	O
,	O
hemorrhagic	B:C0019080
events	O
,	O
or	O
fatal	O
adverse	O
events	I:C0877248
.	O

The	O
addition	O
of	O
angiogenesis	O
inhibitors	I:C0596087
to	O
therapy	O
in	O
ovarian	O
cancer	I:C0029925
did	O
significantly	O
increase	O
the	O
risk	O
of	O
arterial	O
thromboembolic	I:C3544094
events	O
,	O
GI	O
perforation	I:C0151664
,	O
proteinuria	O
and	O
hypertension	O
,	O
but	O
not	O
for	O
venous	O
thromboembolic	I:C1861172
events	O
,	O
hemorrhagic	O
events	O
,	O
or	O
fatal	O
adverse	B:C0877248
events	I:C0877248
.	O

